FDA approves use of Evusheld

FDA approves use of Evusheld

The Food and Drug Administration has approved the use of Evusheld, a combination of long-acting antibodies, for prevention of Covid-19, FDA director Paisal Dankhum said on Wednesday.

Evusheld combines monoclonal antibodies for the prevention, not treatment, of Covid-19. It is not intended to be a substitute for coronavirus vaccines.

It was developed by AstraZeneca and approved by the FDA for emergency use on June 27. It has also been authorised for emergency use by the US Food and Drug Administration and the European Union.

Evusheld is a combination of two active substances, tixagevimab co-packaged with cilgavimab, and works on the principle of "passive immunisation".

It is administered as two injections, with protection lasting for at least six months.

It can be used in adults and children from 12 years of age up weighing at least 40 kilogrammes.

Dr Paisal said people who need to use this medicine should provide doctors with information such as their history of allergies, treatment for coronary artery disease, pregnancy and vaccination history.

Do you like the content of this article?
COMMENT (6)

China's tourism sector hails sudden policy shift on zero-Covid, but lockdown scepticism remains

The night China announced it would ease some of its most controversial coronavirus controls, Shanghai resident Yu Yuan immediately booked a high-speed train ticket to Beijing for a New Year's trip.

15:47

Army hospital first stop for freed athlete Griner

American basketball star Brittney Griner was headed back to the United States on Friday after being released from a Russian prison in exchange for Victor Bout, an arms dealer known as the “Merchant of Death”.

15:42

Energy forecast

Energy consumption expected to increase by 3.2% next year, and a new National Energy Plan that emphasises a swing to use of renewable energy and reduction of greenhouse gas emissions.

15:10